MX2022014238A - Tratamiento combinado de trastornos hepáticos. - Google Patents

Tratamiento combinado de trastornos hepáticos.

Info

Publication number
MX2022014238A
MX2022014238A MX2022014238A MX2022014238A MX2022014238A MX 2022014238 A MX2022014238 A MX 2022014238A MX 2022014238 A MX2022014238 A MX 2022014238A MX 2022014238 A MX2022014238 A MX 2022014238A MX 2022014238 A MX2022014238 A MX 2022014238A
Authority
MX
Mexico
Prior art keywords
combination treatment
liver disorders
agonist
disorders
manifestations
Prior art date
Application number
MX2022014238A
Other languages
English (en)
Inventor
Thorsten A Kirschberg
Kevin Klucher
Martijn Fenaux
Christopher T Jones
Original Assignee
Terns Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Pharmaceuticals Inc filed Critical Terns Pharmaceuticals Inc
Publication of MX2022014238A publication Critical patent/MX2022014238A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporcionan métodos para el tratamiento de trastornos hepáticos, que incluyen esteatohepatitis no alcohólica, y síntomas y manifestaciones de estos, en un paciente, que utilizan, entre otros, un tratamiento combinado con un agonista de FXR y un agonista de THRß.
MX2022014238A 2020-05-13 2021-05-12 Tratamiento combinado de trastornos hepáticos. MX2022014238A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063024360P 2020-05-13 2020-05-13
PCT/US2021/032085 WO2021231646A1 (en) 2020-05-13 2021-05-12 Combination treatment of liver disorders

Publications (1)

Publication Number Publication Date
MX2022014238A true MX2022014238A (es) 2023-04-11

Family

ID=78524975

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022014238A MX2022014238A (es) 2020-05-13 2021-05-12 Tratamiento combinado de trastornos hepáticos.

Country Status (12)

Country Link
US (2) US20210379043A1 (es)
EP (1) EP4149452A4 (es)
JP (1) JP2023525571A (es)
KR (1) KR20230024277A (es)
CN (1) CN115811972A (es)
AU (1) AU2021273487A1 (es)
BR (1) BR112022023048A2 (es)
CA (1) CA3183413A1 (es)
IL (1) IL298144A (es)
MX (1) MX2022014238A (es)
TW (1) TW202207928A (es)
WO (1) WO2021231646A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539639A (ja) 2020-08-25 2023-09-15 イーライ リリー アンド カンパニー Ｓｓａｏ阻害剤の多形
TW202315608A (zh) * 2021-07-06 2023-04-16 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
TW202317110A (zh) * 2021-07-06 2023-05-01 中國大陸商甘萊製藥有限公司 用於治療肝臟疾病的聯合治療
TW202327589A (zh) * 2021-11-11 2023-07-16 美商拓臻製藥公司 肝病之組合療法
CA3238108A1 (en) * 2021-11-11 2023-05-19 Terns Pharmaceuticals, Inc. Treatment of liver disorders with a thr-.beta. agonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170403B1 (en) * 2007-06-27 2014-04-16 Quark Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of pro-apoptotic genes
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
RS59637B1 (sr) * 2014-04-11 2020-01-31 Cymabay Therapeutics Inc Tretiranje nafld i nash
JP2020508316A (ja) * 2017-02-21 2020-03-19 ジェンフィＧｅｎｆｉｔ Ｐｐａｒアゴニストとｆｘｒアゴニストとの組合せ
WO2018208707A1 (en) * 2017-05-08 2018-11-15 Neurovia, Inc. Methods and compositions for treating demyelinating diseases
JP2022508402A (ja) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の治療
CN113056266A (zh) * 2018-09-18 2021-06-29 梅塔科林公司 用于治疗疾病的法尼醇x受体激动剂
CN111320609A (zh) * 2018-12-13 2020-06-23 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途

Also Published As

Publication number Publication date
WO2021231646A1 (en) 2021-11-18
US20210379043A1 (en) 2021-12-09
CN115811972A (zh) 2023-03-17
EP4149452A4 (en) 2024-05-01
IL298144A (en) 2023-01-01
TW202207928A (zh) 2022-03-01
EP4149452A1 (en) 2023-03-22
AU2021273487A1 (en) 2023-01-05
JP2023525571A (ja) 2023-06-16
US20240000765A1 (en) 2024-01-04
KR20230024277A (ko) 2023-02-20
CA3183413A1 (en) 2021-11-18
BR112022023048A2 (pt) 2022-12-20

Similar Documents

Publication Publication Date Title
MX2022014238A (es) Tratamiento combinado de trastornos hepáticos.
MX2022014237A (es) Tratamiento combinado de trastornos hepáticos.
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX2007012353A (es) Metodos para el tratamiento de alteraciones relacionadas con la ansiedad.
DK1885382T3 (da) Fremgangsmåder til anvendelse af adipøst vævs-afledte celler i behandlingen af cardiovaskulære tilstande
EP3447491A3 (en) Diagnosis and treatments relating to th2 inhibition
NO20051545L (no) Ostrogenerstatningsregime
MX350046B (es) Tratamientos para trastornos gastrointestinales.
MX356873B (es) Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.
EA201101568A1 (ru) Лечение ex vivo иммунологических нарушений с помощью ингибиторов pkc-teta
EA200800755A1 (ru) Ikk ингибиторы, предназначенные для лечения эндометриоза
BRPI0506970B8 (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
MX2011012015A (es) Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer.
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
UA94922C2 (ru) Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX2021002305A (es) Tratamiento de trastornos del higado.
MY160406A (en) Combination therapy for pancreatic cancer using an antigenic peptide and chemotherapeutic agent
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
TN2009000136A1 (en) Sequential combination therapy
GB2475660A (en) Methods and kits for treating cluster headache disorders